All Mark T. Gladwin articles
-
NewsNew monoclonal antibody shows promise for preventing malaria infections
A new early-stage clinical trial has found that a novel monoclonal antibody provided dose-dependent full protection against the malaria parasite with minimal side effects.
-
NewsNew vaccine shows promise against typhoid and invasive salmonella in first human trial
Researchers have completed a successful Phase 1 clinical trial of a novel vaccine designed to protect against both typhoid fever and invasive non-typhoidal Salmonella–two major causes of illness and death among children in sub-Saharan Africa.
-
NewsBacterial protein therapy shows promise as first-ever antidote for carbon monoxide poisoning
Researchers have engineered a new molecule that appears promising as an effective antidote for carbon monoxide poisoning with fewer side effects than other molecules currently being tested.
-
NewsMeningococcal vaccine found to be safe and effective for infants in sub-Saharan Africa
A new global health study found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age.
-
NewsVaccine development program aims to prevent sepsis in newborns
Researchers have been awarded $3.96 million to develop a maternal vaccine that prevents sepsis caused by Klebsiella pneumoniae in newborns and infants.
-
NewsResearchers identify new genetic risk factors for persistent HPV infections
A new finding suggests that certain women may have a genetic susceptibility for persistent or frequent HPV infections, potentially raising their risk of getting cervical cancer from a high-risk HPV infection.
-
NewsSingle dose typhoid conjugate vaccine (TCV) provides lasting efficacy in children
A single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old, according to a new study.